Doctors Needed to do a Fast U-Turn

The protocol is the product of a decades-long scientific reversal. In 2000, the American Academy of Pediatrics advised avoiding peanuts until age 3. Peanut allergy prevalence then rose 400–500% in Western countries. Epidemiological data from Israel, where infants routinely consumed peanut snacks, showed dramatically lower allergy rates despite similar genetic backgrounds. This observation led to the LEAP randomized trial, which demonstrated an 86% risk reduction with early introduction. Subsequent guideline updates in 2015, 2017, and 2021 progressively expanded the recommendation to all infants. The speaker emphasizes that real-world data now shows peanut allergy rates falling to near pre-epidemic levels, validating the approach.

The full arc begins with Dr. Rushi Gupta, who followed the avoidance advice yet her daughter developed peanut allergy anyway. The explosion of peanut allergies prompted multiple theories—hygiene hypothesis, microbiome changes, maternal factors—but none fully explained the rapid rise. The critical clue came from the observation that Jewish children in the UK had peanut allergy rates 10 times higher than those in Israel, despite vastly lower peanut consumption. This suggested early oral exposure might be protective, not harmful. Meanwhile, a mechanistic theory emerged: allergic sensitization occurs through the skin, especially when the skin barrier is disrupted by eczema, unless the immune system first encounters the allergen via the gut and builds tolerance. The LEAP study, a randomized controlled trial in 640 high-risk infants, proved that early and frequent peanut consumption reduced allergy risk by 86%. Even among infants who already had a skin-prick sensitivity, eating peanuts cut the allergy rate from 35.3% to 13.7%. These findings forced a complete reversal of medical guidelines. The speaker notes that a recent primary-care database study showed peanut allergy risk fell 35% after the first guideline change and another 10% after the second, bringing prevalence back to about 0.45%, essentially the pre-epidemic level.

The theory posits two routes of exposure: through the skin (or respiratory tract) and through the diet. When the first encounter is via the skin, especially when the skin barrier is compromised by eczema, the immune system often reacts by producing IgE antibodies and mounting an allergic response. When the first encounter is via the mouth and gut, the immune system typically learns to treat the protein as harmless. This explains why children with eczema are at much higher risk of developing peanut allergy—their broken skin barrier let peanut particles enter and initiate sensitization before they ever ate peanut. The saying that summarizes it: 'If it's through the skin, allergies begin. If it's through the diet, they stay quiet.' This framework also clarified why the avoidance advice backfired: by keeping peanuts out of the diet, parents actually increased the chance that environmental exposures through the skin would sensitize their children. The LEAP trial later confirmed that introducing peanut orally before significant skin exposure could prevent allergy, even in genetically at-risk infants.

The study defined three cohorts based on the dates of guideline changes: children born 2012–2014 (pre-new guidelines), 2015–2017 (after the first LEAP-driven recommendation), and 2017–2019 (after the second expansion to moderate-risk infants). The relative risk of developing a peanut allergy fell by 35% after the initial guideline change and a further 10% after the second change. The absolute prevalence in the most recent group was about 0.45%, nearly identical to the 0.4% seen in 1997 before the epidemic. This demonstrates a complete reversal: bad guidelines caused the spike, and good ones undid it. The speaker emphasizes that this is a stunning story of science self-correcting through data.